Year Founded
2009
Ownership
Public
Employees
~10
Stage
Phase 1
Modalities
Small molecule

Incuron General Information

Developing Curaxins targeting FACT complex. Lead candidate CBL0137 in Phase 1 trials for advanced solid tumors with both oral and IV formulations. FACT shown to be marker and target for aggressive cancers.

Contact Information

Website
Primary Industry
Biotech
Corporate Office
,
Russia

Drug Pipeline

CBL0137
Phase 1
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Incuron's pipeline data

Book a demo

Key Partnerships

Cleveland BioLabs, Bioprocess Capital Ventures, Roswell Park Comprehensive Cancer Center

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Incuron Funding

Deal TypeDateAmountStatusStage
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Incuron's complete valuation and funding history, request access »

Incuron Investors

Bioprocess Capital Ventures/Russian Venture Company/VneshEconomBank via fund structure
Investor Type: Venture Capital
Holding: Minority
Cleveland BioLabs/Cytocom
Investor Type: Venture Capital
Holding: Minority